• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

Bringing life-saving care closer to people living with HIV in Kinshasa 

Home > News

Bringing life-saving care closer to people living with HIV in Kinshasa 

10 Jun 2025

A new project being implemented by DNDi in partnership with PNLS, the national AIDS programme of the Democratic Republic of the Congo (DRC), is bringing new hope to people living with advanced HIV disease (AHD) in Kinshasa, DRC. Forming part of the Improved Access to AHD Care and Treatment for HIV (IMPAACT4HIV) consortium led by the Aurum Institute and funded by UNTAID, the project is strengthening local health system capacity to screen, diagnose, and treat opportunistic infections – significantly reducing travel and wait times at referral centers and improving access to timely diagnosis and treatment.  

Between 29 April and 5 June 2025, over 70 healthcare workers and members of civil society organizations in Kinshasa, DRC, took part in capacity-strengthening sessions conducted by Médecins Sans Frontières (MSF). The theoretical and practical training aimed to strengthen the ability of healthcare providers, especially in primary healthcare facilities, to manage AHD and improve access to care for people living with HIV. Civil society representatives, including communities of people living with HIV, were also involved to ensure their needs and perspectives were reflected throughout the process.  

Healthcare workers practice key lab skills during IMPAACT4HIV training to improve diagnosis and treatment of AHD

Despite progress in antiretroviral therapy, AHD continues to cause preventable deaths. In 2023 alone, around 11,000 out of an estimated 520,000 people living with HIV in the DRC lost their lives to AIDS-related illnesses.

‘It is a great tragedy that in 2025, people are still dying from AIDS-related opportunistic infections when we already have the tools to treat them,’ said Chirac Bulanga, Director of the DNDi DRC Regional Office. ‘By bringing life-saving medicines directly into local clinics, rather than only at referral hospitals miles away, we can prevent more AIDS deaths, especially in the face of funding cuts that risk treatment interruptions and more cases of AHD.’ 

The healthcare professionals trained gained practical skills to identify AHD cases effectively, while also enhancing their understanding of the connections between tuberculosis, anaemia, meningitis, and HIV. This knowledge is critical for delivering appropriate and timely care.  

Dr César Mantuala

’This training is essential because it allows us to improve the quality of healthcare services and manage respiratory complications related to HIV more effectively,’ said Dr César Mantuala, Chief Medical Officer of Lemba. 

 ‘What we’ve learned is already helping us recognize the signs of AHD and adjust our care accordingly,’ shares another participant, Anderson Mbuyi, HIV focal point at Maman Pamela Health Center, Kasavubu, highlighting the direct impact of the training. 

The practical phase of the training took place from 21 May to 5 June 2025 at an MSF site, allowing healthcare providers to apply the tools and protocols discussed during the theoretical sessions. 

Dr Rosalie Kandolo, a doctor at the Kasaï Referral Health Center in Barumbu, reflects on the tangible impact of the training:

‘We were already aware of the complications associated with HIV, but this training has allowed us to better understand how to respond practically. We learned how to make diagnoses faster using tests that we can perform on site, without waiting hours for laboratory results. This completely changes patient care. We now know how to navigate specific pathologies, especially respiratory ones, and make accurate differential diagnoses.’

Dr Rosalie Kandolo

Dr Don Nzeza, focal point of the DRC national AIDS control program (PNLS) in Kinshasa, sums up the importance of this initiative: ‘Every life saved is a victory for humanity. The IMPAACT4HIV project, a true catalyst and a remarkable demonstration of efficiency, opens a crucial path of hope. It ensures quick and effective care for patients with AHD, despite the major organizational challenges in our context.’ 

Strengthening Capacities Cryptococcal meningitis Africa

Read, watch, share

Loading...
Statements
3 Feb 2026

DNDi interventions at the 158th Session of the WHO Executive Board

Sir Nicholas White
News
2 Feb 2026

Message on the passing of Professor Sir Nicholas White from DNDi Board Chair Dr Marie-Paule Kieny and DNDi Executive Director Dr Luis Pizarro

News
30 Jan 2026

Imperial and DNDi strengthen partnership to accelerate treatments for neglected diseases 

News
30 Jan 2026

Science can end the neglect: but only if we act together – World NTD Day 2026

From risk to remedy: Fast-tracking the end of sleeping sickness
Videos
28 Jan 2026

From risk to remedy: Fast-tracking the end of sleeping sickness

Dr Joseph Gichuru, Deputy Executive Director and the Director of Operations, APHRC, and Prof. Samuel Kariuki, Continental Lead Africa and Eastern Africa Director, DNDi
News
27 Jan 2026

DNDi and APHRC sign MoU to forge strategic alliance to bridge research and capacity enhancement gaps

Statements
23 Jan 2026

DNDi’s briefing note for 158th Session of the WHO Executive Board

News
16 Dec 2025

DNDi 2025 in Review

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license